NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research

Summary & key facts

This paper is a review of research on a brain protein called the NMDA receptor and how drugs that change its activity might treat depression. The authors summarize human clinical studies and lab work in animals. They explain that ketamine, a drug that blocks NMDA receptors, can lift depression symptoms quickly in people who do not get better with standard antidepressants. The review also describes several possible brain mechanisms for ketamine’s effects, points out that many findings come from animal studies, and says new tools like high-resolution imaging and computer-aided drug design could help create better, fast-acting antidepressants in the future.

Key facts:

• Ketamine blocks a specific brain receptor called the NMDA receptor, and this action can produce fast and sometimes lasting antidepressant effects in people whose depression did not improve with usual medicines.
• Researchers think problems with glutamate, the brain’s main excitatory chemical, are linked to depression, which is why drugs that affect NMDA receptors are getting attention.
• One proposed mechanism is that ketamine blocks NMDA receptors on inhibitory nerve cells (called GABAergic interneurons). That can release the brake on other brain cells and boost overall activity in circuits related to mood.
• The review describes differences between NMDA receptors found at synapses (the direct contact points between neurons) and those outside synapses, and says these locations may have different roles in how ketamine works.
• Many of the detailed mechanisms come from studies in genetically altered rodents or other lab models, so it is still uncertain how exactly those findings map onto people.
• The authors point to new technologies, like cryo-electron microscopy (a way to image proteins at very high resolution) and artificial-intelligence drug design, as promising tools to develop next-generation rapid antidepressants that target NMDA receptors.

Topics

Neuroscience and Neuropharmacology Research Treatment of Major Depression Tryptophan and brain disorders

Categories

Health Sciences Medicine Pharmacology

Tags

Antidepressant Glutamate receptor Glutamatergic Hippocampus Internal medicine Ketamine Medicine Memantine Monoaminergic Neuroscience NMDA receptor Pharmacology Psychology Receptor Serotonin

Substances

Ketamine

Conditions & symptoms

Depression Lack of energy or motivation Sadness or low mood